Chiome Bioscience Inc
TSE:4583
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
81
180
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Gross Margin
Chiome Bioscience Inc
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | JP |
| Market Cap | 11B JPY |
| Gross Margin |
54%
|
| Country | US |
| Market Cap | 1.3T USD |
| Gross Margin |
55%
|
| Country | US |
| Market Cap | 196.3B USD |
| Gross Margin |
41%
|
| Country | US |
| Market Cap | 170.3B USD |
| Gross Margin |
60%
|
| Country | KR |
| Market Cap | 66.5T KRW |
| Gross Margin |
50%
|
| Country | CH |
| Market Cap | 37.6B CHF |
| Gross Margin |
29%
|
| Country | US |
| Market Cap | 38.5B USD |
| Gross Margin |
55%
|
| Country | US |
| Market Cap | 36.7B USD |
| Gross Margin |
35%
|
| Country | US |
| Market Cap | 26.4B USD |
| Gross Margin |
59%
|
| Country | US |
| Market Cap | 23B USD |
| Gross Margin |
35%
|
| Country | US |
| Market Cap | 22.3B USD |
| Gross Margin |
64%
|
Chiome Bioscience Inc
Glance View
Chiome Bioscience, Inc. engages in the development and sale of antibody drugs through the Autonomous Diversifying Library (ADLib) system. The company is headquartered in Shibuya-Ku, Tokyo-To and currently employs 37 full-time employees. The company went IPO on 2011-12-20. The firm operates in two business segments. The Drug Discovery segment is engaged in the research and development of specific antibodies based on new antigens and mechanisms and licensing to pharmaceutical companies. The Drug Discovery Support segment is engaged in development of lead antibodies for therapeutic drugs in collaborating with pharmaceutical companies in Japan and overseas.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Chiome Bioscience Inc's most recent financial statements, the company has Gross Margin of 53.6%.
You don't have any saved screeners yet
